Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.46 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27727584 | 0.98 | HPGD (0.52) | HPGDHCAR2DAOHCAR3CYTH3 | |
| SCHEMBL4755850 | 0.87 | MAPK1 (0.51) | HPGDHCAR2DAOHCAR3CYTH3 | |
| SCHEMBL5969919 | 0.83 | HPGD (0.52) | HPGDHCAR2DAOCYTH3BTK | |
| SCHEMBL15981916 | 0.83 | HPGD (0.52) | HPGDHCAR2DAOHCAR3 | |
| SCHEMBL5013388 | 0.83 | HPGD (0.52) | HPGDHCAR2DAOCYTH3BTK | |
| SCHEMBL42514 | 0.83 | HPGD (0.52) | HPGDHCAR2DAO | |
| SCHEMBL17928435 | 0.83 | HPGD (0.49) | HPGDHCAR2DAOHCAR3CYTH3 | |
| SCHEMBL18680106 | 0.79 | HPGD (0.49) | HPGDHCAR2DAOHCAR3 | |
| SCHEMBL25449 | 0.79 | MAPK1 (0.57) | HPGDHCAR2 | |
| SCHEMBL6305513 | 0.79 | HPGD (0.49) | HPGDHCAR2DAOHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| CN-119638705-A | Energetic compound taking polyaminotriazole as framework, energetic ionic salt and preparation method thereof | 南京理工大学 | 2025-03-18 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | claimed |
| CN-1878769-A | Cytokine inhibitors | KEMIA INC (US) | 2006-12-13 | — | — | CN | claimed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| US-7005439-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-02-28 | — | — | US | claimed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| EP-1299356-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-11 | — | — | EP | claimed |
| CN-1447794-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | CN | claimed |
| EP-1299356-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | claimed |
| WO-2001098272-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | claimed |
| US-12577266-B2 | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| WO-1998054702-A1 | MAGNETIC RECORDING MEDIA INCORPORATING SURFACE TREATED MAGNETIC PIGMENT | IMATION CORP. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | HPGD 3676/4885HCAR2 4789/4885DAO 895/4885 |
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | HPGD 518/4885HCAR2 281/4885DAO 1926/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | HPGD 3676/4885HCAR2 4789/4885DAO 895/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | HPGD 3676/4885HCAR2 4789/4885DAO 895/4885 |
| US-12577266-B2 | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens | ACP1, AOX1, PTMS | HPGD 1327/4885HCAR2 3840/4885DAO 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.